Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $39
Benzinga Newsdesk 4 hours ago
Analyst RatingsNewsPrice Target
Mizuho analyst Graig Suvannavejh maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $38 to $39.
Mizuho analyst Graig Suvannavejh maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $38 to $39.